DK1809237T3 - Ophthalmisk olie-i-vand emulsion med stabilt positivt zeta-potentiale - Google Patents

Ophthalmisk olie-i-vand emulsion med stabilt positivt zeta-potentiale

Info

Publication number: DK1809237T3
Authority: DK; Denmark
Prior art keywords: water emulsion; zeta potential; positive zeta; stable positive; ophthalmic oil
Prior art date: 2004-11-09

Application number

DK05795930T

Other languages

English (en)

Inventor

Laura Rabinovich-Guilatt

Gregory Lambert

Severine Bague

Betty Philips

Jean-Sebastien Garrigue

Original Assignee

Novagali Pharma Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-11-09

Filing date

2005-10-10

Publication date

2009-05-04

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34931510&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1809237(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-10-10 Application filed by Novagali Pharma Sa filed Critical Novagali Pharma Sa

2005-10-10 Priority claimed from PCT/EP2005/011650 external-priority patent/WO2006050838A2/en

2009-05-04 Application granted granted Critical

2009-05-04 Publication of DK1809237T3 publication Critical patent/DK1809237T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Ophthalmology & Optometry (AREA)
Epidemiology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Dispersion Chemistry (AREA)
Biophysics (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Virology (AREA)
Heart & Thoracic Surgery (AREA)
Transplantation (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Materials For Medical Uses (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Colloid Chemistry (AREA)
Cosmetics (AREA)

DK05795930T 2004-11-09 2005-10-10 Ophthalmisk olie-i-vand emulsion med stabilt positivt zeta-potentiale DK1809237T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP04292645A EP1655021B1 (en)	2004-11-09	2004-11-09	Oil-in-water type emulsion with low concentration of cationic agent and positive zeta potential
US10/991,346 US8298568B2 (en)	2004-11-09	2004-11-18	Oil-in-water type emulsion with low concentration of cationic agent and positive zeta potential
PCT/EP2005/011650 WO2006050838A2 (en)	2004-11-09	2005-10-10	Ophthalmic oil-in-water type emulsion with stable positive zeta potential

Publications (1)

Publication Number	Publication Date
DK1809237T3 true DK1809237T3 (da)	2009-05-04

Family

ID=34931510

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK05795930T DK1809237T3 (da)	2004-11-09	2005-10-10	Ophthalmisk olie-i-vand emulsion med stabilt positivt zeta-potentiale

Country Status (13)

Country	Link
US (5)	US8298568B2 (da)
EP (1)	EP1655021B1 (da)
JP (3)	JP5587936B2 (da)
CN (3)	CN101014317A (da)
AT (5)	ATE412400T1 (da)
DE (5)	DE602004017477D1 (da)
DK (1)	DK1809237T3 (da)
ES (4)	ES2314354T3 (da)
IL (3)	IL181446A (da)
MX (2)	MX2007005545A (da)
NZ (1)	NZ554929A (da)
PT (2)	PT1809238E (da)
ZA (1)	ZA200703751B (da)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8232320B2 (en)	1999-04-28	2012-07-31	The Regents Of The University Of Michigan	Antimicrobial nanoemulsion compositions and methods
US7767216B2 (en)	1999-04-28	2010-08-03	The Regents Of The University Of Michigan	Antimicrobial compositions and methods of use
US7655252B2 (en)	1999-04-28	2010-02-02	The Regents Of The University Of Michigan	Antimicrobial nanoemulsion compositions and methods
US20050208083A1 (en)	2003-06-04	2005-09-22	Nanobio Corporation	Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof
EP1655021B1 (en) *	2004-11-09	2008-10-29	Novagali Pharma SA	Oil-in-water type emulsion with low concentration of cationic agent and positive zeta potential
US20070054834A1 (en) *	2005-04-11	2007-03-08	Nanobio Corporation	Quaternary ammonium halides for treatment of infectious conditions
US7297679B2 (en) *	2005-07-13	2007-11-20	Allergan, Inc.	Cyclosporin compositions
JP2009504805A (ja) *	2005-08-09	2009-02-05	ナノバイオコーポレーション	抗炎症活性を有するナノエマルジョン組成物
US7797337B2 (en) *	2005-09-29	2010-09-14	Scenera Technologies, Llc	Methods, systems, and computer program products for automatically associating data with a resource as metadata based on a characteristic of the resource
WO2007103294A2 (en) *	2006-03-07	2007-09-13	Novavax, Inc.	Nanoemulsions of poorly soluble pharmaceutical active ingredients and methods of making the same
US11311477B2 (en)	2006-03-07	2022-04-26	Sgn Nanopharma Inc.	Ophthalmic preparations
US10137083B2 (en) *	2006-03-07	2018-11-27	SGN Nanopharma Inc	Ophthalmic preparations
CA2681668C (en)	2006-03-23	2014-04-01	Michael S. Singer	Compositions comprising prostaglandin f2-alpha analogs and methods for reducing body fat
US20080026013A1 (en) *	2006-07-28	2008-01-31	Laura Rabinovich-Guilatt	Compositions containing quaternary ammonium compounds
WO2008035246A2 (en) *	2006-07-28	2008-03-27	Novagali Pharma Sa	Compositions containing quaternary ammonium compounds
AU2014201978B2 (en) *	2006-07-28	2016-03-10	Santen Sas	Compositions containing quaternary ammonium compounds
US9132071B2 (en) *	2006-07-28	2015-09-15	Santen Sas	Compositions containing quaternary ammonium compounds
DK1891939T3 (da) *	2006-07-28	2013-10-07	Novagali Pharma Sa	Sammensætninger indeholdende kvaternære ammoniumforbindelser
EP2444829A1 (en)	2006-09-14	2012-04-25	Carl Zeiss SMT GmbH	Optical element unit and method of supporting an optical element
EP1938801A1 (en) *	2006-12-22	2008-07-02	Biofrontera Bioscience GmbH	Nanoemulsion
EP1985298A1 (en)	2007-04-24	2008-10-29	Azad Pharma AG	Ophtalmic oil-in-water emulsions containing prostaglandins
US8747872B2 (en)	2007-05-02	2014-06-10	The Regents Of The University Of Michigan	Nanoemulsion therapeutic compositions and methods of using the same
US20090018057A1 (en) *	2007-07-09	2009-01-15	Gregory Lambert	OIL IN WATER EMULSION COMPRISING NSAIDs AND QUATERNARY AMMONIUM HALIDES
US8512687B2 (en) *	2007-07-09	2013-08-20	Novagali Pharma Sa	Oil in water emulsion comprising NSAIDs and quaternary ammonium halides
US9125807B2 (en)	2007-07-09	2015-09-08	Incept Llc	Adhesive hydrogels for ophthalmic drug delivery
EP2197449A4 (en) *	2007-10-16	2013-10-09	Sun Pharma Advanced Res Co Ltd	NOVEL OPHTHALMIC COMPOSITIONS
WO2009063081A2 (en) *	2007-11-14	2009-05-22	Novagali Pharma Sa	Composition comprising at least one nucleosidic moiety as a therapeutic agent, and ckc.
US7834172B2 (en) *	2007-11-14	2010-11-16	Novagali Pharma Sa	Composition comprising at least one nucleosidic moiety as a therapeutic agent, and CKC
EP2077104A1 (en) *	2008-01-02	2009-07-08	Novagali Pharma SA	Micellar compositions with ophtalmic applications
EP2077105A1 (en) *	2008-01-02	2009-07-08	Novagali Pharma SA	Ophthalmic Micellar Compositions with Enhanced Stability
EP2127638A1 (en) *	2008-05-30	2009-12-02	Santen Pharmaceutical Co., Ltd	Method and composition for treating ocular hypertension and glaucoma
BRPI0918244A2 (pt) *	2008-09-04	2015-12-15	Santen Pharmaceutical Co Ltd E Asahi Glass Company Ltd	agente promotor do crescimento de pelos, e método para prevenir ou tratar uma doença associada com os cabelos.
PL2331128T3 (pl) *	2008-09-05	2014-06-30	Ceva Sante Animale Sa	Kompozycja zawierająca chitozan do doocznego podawania szczepionki (szczepionek) ptakom
WO2010057197A1 (en)	2008-11-17	2010-05-20	The Regents Of The University Of Michigan	Cancer vaccine compositions and methods of using the same
US8409606B2 (en)	2009-02-12	2013-04-02	Incept, Llc	Drug delivery through hydrogel plugs
EP2228058A1 (en)	2009-03-04	2010-09-15	Novagali Pharma S.A.	Anionic oil-in-water emulsion containing prostaglandins and uses thereof
EP2228057A1 (en) *	2009-03-04	2010-09-15	Novagali Pharma S.A.	Cationic oil-in-water emulsions containing prostaglandins and uses thereof
US8299079B2 (en)	2009-05-22	2012-10-30	Kaufman Herbert E	Preparations and methods for ameliorating or reducing presbyopia
US20100298335A1 (en) *	2009-05-22	2010-11-25	Kaufman Herbert E	Preparations and Methods for Ameliorating or Reducing Presbyopia
US20110112198A1 (en) *	2009-11-09	2011-05-12	Allergan, Inc.	Compositions for enhancing hair growth
EP2389939A1 (en) *	2010-05-28	2011-11-30	Novagali Pharma S.A.	Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions
US10154923B2 (en)	2010-07-15	2018-12-18	Eyenovia, Inc.	Drop generating device
JP2013531044A (ja) *	2010-07-15	2013-08-01	コリンシアンオフサルミック，インコーポレイティド	点眼薬送達
US10272040B2 (en)	2010-08-12	2019-04-30	Nanyang Technological University	Liposomal formulation for ocular drug delivery
US8961501B2 (en)	2010-09-17	2015-02-24	Incept, Llc	Method for applying flowable hydrogels to a cornea
EP2982373B1 (en)	2011-01-19	2018-06-13	Topokine Therapeutics, Inc.	Methods and compostions for reducing body fat
EP2667877B1 (en)	2011-01-26	2018-03-07	Allergan, Inc.	Androgen composition for treating an ophthalmic condition
EP2734261B1 (en)	2011-07-18	2018-02-21	Mor-Research Applications Ltd.	A device for adjusting the intraocular pressure
US10226417B2 (en)	2011-09-16	2019-03-12	Peter Jarrett	Drug delivery systems and applications
EP3701939A1 (en) *	2011-11-15	2020-09-02	Allergan, Inc.	Suspensions of cyclosporin a form 2
AU2012339701B8 (en)	2011-11-15	2017-11-16	Allergan, Inc.	Autoclavable suspensions of cyclosporin A Form 2
AU2012347926B2 (en)	2011-12-05	2018-03-15	Incept, Llc	Medical organogel processes and compositions
US8426471B1 (en)	2011-12-19	2013-04-23	Topokine Therapeutics, Inc.	Methods and compositions for reducing body fat and adipocytes
JP5992031B2 (ja) *	2012-02-24	2016-09-14	ファインバイオメディカル有限会社	潤滑性調整液
US8980839B2 (en)	2012-08-24	2015-03-17	Ocular Technologies Sarl	Topical aqueous nanomicellar, ophthalmic solutions and uses thereof
US9987367B2 (en) *	2012-09-06	2018-06-05	Nanyang Technological University	Hyaluronic acid-based drug delivery systems
US8778981B2 (en)	2012-11-21	2014-07-15	Topokine Therapeutics, Inc.	Methods and compositions for locally increasing body fat
EP2948134B1 (en)	2013-01-24	2020-03-04	Palvella Therapeutics, Inc.	Compositions for transdermal delivery of mtor inhibitors
ES2930433T3 (es)	2013-03-05	2022-12-12	Univ Pittsburgh Commonwealth Sys Higher Education	Hidrogel termosensible que contiene micropartículas de polímero para la administración ocular no invasiva de fármaco
WO2014142146A1 (ja) *	2013-03-13	2014-09-18	参天製薬株式会社	マイボーム機能不全の治療剤
US20140275261A1 (en) *	2013-03-15	2014-09-18	Dr. Reddy's Laboratories, Inc.	Diclofenac parenteral compositions
RU2513597C1 (ru) *	2013-04-17	2014-04-20	Федеральное государственное бюджетное учреждение "Научно-исследовательский институт глазных болезней" Российской академии медицинских наук (ФГБУ "НИИГБ" РАМН)	Способ лечения воспалительных состояний переднего отрезка глаза
NO2753788T3 (da)	2013-05-10	2018-06-16
US9820993B2 (en)	2013-05-15	2017-11-21	Topokine Therapeutics, Inc.	Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
EP3013790A1 (en)	2013-06-27	2016-05-04	Mylan Laboratories Ltd.	Process for the preparation of nepafenac
US9956195B2 (en)	2014-01-07	2018-05-01	Nanyang Technological University	Stable liposomal formulations for ocular drug delivery
CA2939562C (en)	2014-02-11	2023-02-14	Dr. Reddy's Laboratories Ltd.	Parenteral compositions of celecoxib
WO2015123631A1 (en) *	2014-02-14	2015-08-20	Jingjun Huang	Compositions of nanoemulsion delivery systems
US20170087096A1 (en) *	2014-06-13	2017-03-30	Sanofi	Nanocapsular formulation of active pharmaceutical ingredients
WO2015200425A1 (en)	2014-06-27	2015-12-30	Topokine Therapeutics, Inc.	Topical dosage regimen
JP2017538728A (ja) *	2014-12-19	2017-12-28	ケミン、インダストリーズ、インコーポレーテッドＫｅｍｉｎＩｎｄｕｓｔｒｉｅｓ，Ｉｎｃ．	イオントフォレシスを用いた生物活性分子の眼内送達
US11324800B2 (en)	2015-01-15	2022-05-10	Wellspring Ophthalmics, Inc.	Aqueous suspensions of cyclosporin
US20200237859A1 (en)	2019-01-25	2020-07-30	Newport Research, Inc.	Aqueous suspensions of cyclosporin
AU2016215182B2 (en) *	2015-02-06	2019-09-12	R. P. Scherer Technologies, Llc	Preparation of an oil-in-water emulsion for polymer stabilized pharmaceutical formulations
CN106176600A (zh) *	2015-05-07	2016-12-07	上海现代药物制剂工程研究中心有限公司	一种前列地尔冻干微乳剂、原料组合物及其制备方法
WO2016182926A1 (en) *	2015-05-08	2016-11-17	Affinsci Inc.	Preparation of nanoemulsions
PL3373976T3 (pl)	2015-11-10	2024-06-24	Sun Pharmaceutical Industries Limited	Preparaty do stosowania miejscowego i ich zastosowanie
US10918694B2 (en)	2016-02-29	2021-02-16	Sun Pharma Global Fze	Topical cyclosporine-containing formulations and uses thereof
JP6906899B2 (ja) *	2016-03-30	2021-07-21	小林製薬株式会社	乳化組成物
JP6774508B2 (ja)	2016-05-03	2020-10-28	ニューマ・リスパイラトリー・インコーポレイテッド	流体を肺系に供給するための液滴送達装置、及びその使用方法
WO2017192773A1 (en)	2016-05-03	2017-11-09	Pneuma Respiratory, Inc.	Methods for treatment of pulmonary lung diseases with improved therapeutic efficacy and improved dose efficiency
US11285274B2 (en)	2016-05-03	2022-03-29	Pneuma Respiratory, Inc.	Methods for the systemic delivery of therapeutic agents to the pulmonary system using a droplet delivery device
EP4591994A3 (en)	2016-05-03	2025-10-01	Pneuma Respiratory, Inc.	A droplet delivery device for generating and delivering droplets to the pulmonary system
WO2017192782A1 (en)	2016-05-03	2017-11-09	Pneuma Respiratory, Inc.	Systems and methods comprising a droplet delivery device and a breathing assist device for therapeutic treatment
US11395853B2 (en)	2016-06-23	2022-07-26	University Of Pittsburgh - Of The Commonwealth System Of Higher Education	Biomimetic drug delivery of an immunomodulatory agent for the treatment of ocular conditions
DK3266446T3 (da) *	2016-07-07	2019-02-11	Salvat Lab Sa	Øjenpræparat omfattende ricinusolie og triglycerid med mediumkæde
CN106782348A (zh) *	2017-01-04	2017-05-31	深圳市华星光电技术有限公司	一种led背光驱动电路及液晶显示器
IL267869B2 (en)	2017-01-06	2023-10-01	Palvella Therapeutics Inc	Non-aqueous preparations of mTOR inhibitors and methods of use
CA3064005C (en)	2017-05-19	2023-03-07	Pneuma Respiratory, Inc.	Dry powder delivery device and methods of use
KR20200069261A (ko) *	2017-05-30	2020-06-16	엑시모어 엘티디.	항생제 마크로라이드를 전달하는 안구건조증을 치료하기 위한 조성물 및 방법
AU2018279940B2 (en)	2017-06-10	2023-12-14	Eyenovia, Inc.	Methods and devices for handling a fluid and delivering the fluid to the eye
WO2019071008A1 (en)	2017-10-04	2019-04-11	Pneuma Respiratory, Inc.	ELECTRONIC DEVICE FOR DELIVERY OF LINEAR SHAPE ADMINISTRATION OPERATED BY BREATHING AND METHODS OF USE
CA3079189A1 (en)	2017-10-17	2019-04-25	Pneuma Respiratory, Inc.	Nasal drug delivery apparatus and methods of use
US11253480B2 (en)	2017-10-30	2022-02-22	University of Pittsburgh—of the Commonwealth System of Higher Education	Treatment of ocular conditions utilizing a histone/protein deacetylase inhibitor
CA3082192A1 (en)	2017-11-08	2019-05-16	Pneuma Respiratory, Inc.	Electronic breath actuated in-line droplet delivery device with small volume ampoule and methods of use
WO2019162951A1 (en) *	2018-02-26	2019-08-29	Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd	Drug delivery systems
JP2021530463A (ja)	2018-07-02	2021-11-11	パルヴェラセラピューティクス、インク．	ｍＴＯＲ阻害剤の無水組成物および使用方法
CN109010268B (zh) *	2018-09-28	2020-07-10	湖北远大天天明制药有限公司	一种提高氯霉素稳定性的眼用组合物及其制备方法
SG11202106144VA (en)	2018-12-11	2021-07-29	Disruption Labs Inc	Compositions for the delivery of therapeutic agents and methods of use and making thereof
CN110237233B (zh) *	2019-07-30	2021-01-15	沈阳兴齐眼药股份有限公司	一种含有环孢素的眼用药物组合物、其制备方法及用途
EP4069220A4 (en) *	2019-12-04	2024-04-24	Restore Vision, LLC.	OPHTHALMIC FORMULATIONS FOR THE TREATMENT OF PRESBYOPIA
CA3164288A1 (en)	2019-12-11	2021-06-17	Eyenovia, Inc.	Systems and devices for delivering fluids to the eye and methods of use
WO2021252484A1 (en) *	2020-06-10	2021-12-16	Disruption Labs Inc.	Compositions for the delivery of therapeutic agents and methods of use and making thereof
PL4359046T3 (pl)	2021-06-22	2025-10-13	Pneuma Respiratory, Inc.	Urządzenie do podawania kropelkowego z wyrzutem wypychającym
US12236866B2 (en)	2021-07-30	2025-02-25	Boe Technology Group Co., Ltd.	Pixel circuit, driving method and display device
CN113577024B (zh) *	2021-08-20	2023-05-05	山西利普达医药科技有限公司	一种眼用组合物及其制备方法和应用
CN116407499B (zh) *	2021-12-29	2024-10-25	辅必成（上海）医药科技有限公司	一种他克莫司眼用乳剂及其制备方法
KR20250038748A (ko)	2022-07-18	2025-03-19	뉴마 레스퍼러토리 인코포레이티드	작은 스텝 크기 및 고해상도 에어로졸 생성 시스템 및 방법
WO2024208434A1 (en)	2023-04-06	2024-10-10	Biofrontera Bioscience Gmbh	Pressurized nanoemulsion
WO2024208433A1 (en)	2023-04-06	2024-10-10	Biofrontera Bioscience Gmbh	Nanoemulsion without propylene glycol
WO2025030169A2 (en) *	2023-08-03	2025-02-06	Arcum Vision Inc.	Enhanced formulation of polymyxin b/ trimethoprim and rifampin and methods for ophthalmic uses

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4599353A (en) *	1982-05-03	1986-07-08	The Trustees Of Columbia University In The City Of New York	Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
JPH0818989B2 (ja) *	1984-01-12	1996-02-28	株式会社ミドリ十字	脂肪乳剤中のプロスタグランジンの安定化方法
US4839342A (en)	1987-09-03	1989-06-13	University Of Georgia Research Foundation, Inc.	Method of increasing tear production by topical administration of cyclosporin
JP2602964B2 (ja)	1989-10-16	1997-04-23	裕水島	プロスタグランジン類縁体およびその脂肪乳剤
IL101241A (en) *	1992-03-16	1997-11-20	Yissum Res Dev Co	Pharmaceutical or cosmetic composition comprising stabilized oil-in-water type emulsion as carrier
SG49746A1 (en) *	1992-08-28	1998-06-15	Pharmos Corp	Submicron emulsions as ocular drug delivery vehicles
IL103907A0 (en) *	1992-11-27	1993-04-04	Pharmos Corp	Ophthalmic compositions
US5688819A (en) *	1992-09-21	1997-11-18	Allergan	Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
JP3551977B2 (ja) *	1993-04-08	2004-08-11	ライオン株式会社	安定なビタミンａ類及びビタミンｅ類可溶化点眼剤
DE69411816T2 (de) *	1993-06-25	1998-12-03	Alcon Cusi, S.A., El Masnou, Barcelona	Neue Verwendung von polymeren Membranen zum Ausgeben von pharmazeutischen Lösungen, die quarternäre, als Konserviermittel dienende Ammoniumverbindungen enthalten und entsprechender Dosierbehälter
US5510383A (en) *	1993-08-03	1996-04-23	Alcon Laboratories, Inc.	Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
AU2577295A (en) *	1994-06-01	1995-12-21	Yuhan Corporation	Cyclosporin containing composition and process for the preparation thereof
ES2094688B1 (es) *	1994-08-08	1997-08-01	Cusi Lab	Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
US6011062A (en) *	1994-12-22	2000-01-04	Alcon Laboratories, Inc.	Storage-stable prostaglandin compositions
US5631287A (en) *	1994-12-22	1997-05-20	Alcon Laboratories, Inc.	Storage-stable prostaglandin compositions
US5767153A (en) *	1995-06-07	1998-06-16	Insite Vision Incorporated	Sustained release emulsions
JP3410364B2 (ja) *	1997-05-14	2003-05-26	千寿製薬株式会社	ジフルプレドナート含有組成物
EP0878197B1 (en)	1997-05-14	2002-08-21	Senju Pharmaceutical Co., Ltd.	Compositions containing difluprednate
US6066671A (en) *	1997-12-19	2000-05-23	Alcon Laboratories, Inc.	Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
US6225348B1 (en) *	1998-08-20	2001-05-01	Alfred W. Paulsen	Method of treating macular degeneration with a prostaglandin derivative
WO2000038663A2 (en) *	1998-12-24	2000-07-06	Alcon Laboratories, Inc.	Ep4 receptor agonists for treatment of dry eye
US20020136771A1 (en) *	1998-12-31	2002-09-26	Amitee Cosmetics, Inc.	Stabilized ascorbic acid composition
FR2823441B1 (fr) *	2001-04-12	2004-09-10	Thea Lab	Composition pharmaceutique a base de macrolides pour application locale en ophtalmologie et son procede de preparation
US20040198829A1 (en) *	2001-04-23	2004-10-07	Sponsel William Eric	Prostanoids augment ocular drug penetration
US7314624B2 (en) *	2001-06-05	2008-01-01	The Regents Of The University Of Michigan	Nanoemulsion vaccines
US6872705B2 (en) *	2001-07-13	2005-03-29	Allergan, Inc.	Use of antimicrobial peptides as preservatives in ophthalmic preparations, including solutions, emulsions, and suspensions
AU2002214233A1 (en) *	2001-11-01	2003-07-09	Novagali Pharma Sa	Method and composition for dry eye treatment
US6656460B2 (en) *	2001-11-01	2003-12-02	Yissum Research Development	Method and composition for dry eye treatment
KR100446960B1 (ko)	2001-12-04	2004-09-01	김종국	프로스타글란딘 ｅ1을 포함하는 온도감응성 에멀젼 외용제조성물
US20030165545A1 (en) *	2002-01-30	2003-09-04	Allergan, Inc.	Ophthalmic compositions including oil-in-water emulsions, and methods for making and using same
US20050124699A1 (en) *	2002-07-02	2005-06-09	Wakamoto Pharmaceutical Co., Ltd.	Drugs for treating or preventing disorders of corneal and/or conjunctival epithelial cells
CN100361661C (zh)	2002-08-23	2008-01-16	参天制药株式会社	以拉坦前列素为有效成分的稳定的滴眼液
AU2003261981A1 (en)	2002-09-09	2004-03-29	Santen Pharmaceutical Co., Ltd.	Transparent eye drops containing latanoprost
US20040115234A1 (en) *	2002-09-24	2004-06-17	Gewirtz Joan T.	Cosmetic composition
US7074827B2 (en) *	2002-10-24	2006-07-11	Sucampo Ag (Usa) Inc.	Method for treating ocular hypertension and glaucoma
JP4361294B2 (ja) *	2003-02-25	2009-11-11	ロート製薬株式会社	ケトチフェン含有組成物
JP4694773B2 (ja) *	2003-06-06	2011-06-08	ロート製薬株式会社	粘膜適用液状組成物
US20050059583A1 (en)	2003-09-15	2005-03-17	Allergan, Inc.	Methods of providing therapeutic effects using cyclosporin components
JP5382972B2 (ja) *	2003-12-26	2014-01-08	ロート製薬株式会社	粘度低下が防止された組成物
US20050175651A1 (en) *	2004-01-09	2005-08-11	L'oreal	Aqueous dispersion of nanocapsules with an oily core
ATE439123T1 (de)	2004-07-02	2009-08-15	Novagali Pharma Sa	Verwendung von emulsionen zur intra- und periocularen injection
JP4999304B2 (ja) *	2004-09-27	2012-08-15	ロート製薬株式会社	ヒアルロン酸又はその塩を含有する粘膜適用組成物
EP1809237B1 (en) *	2004-11-09	2008-12-31	Novagali Pharma SA	Ophthalmic oil-in-water type emulsion with stable positive zeta potential
EP1655021B1 (en) *	2004-11-09	2008-10-29	Novagali Pharma SA	Oil-in-water type emulsion with low concentration of cationic agent and positive zeta potential
US20090170944A1 (en) *	2008-01-02	2009-07-02	Novagali Pharma Sa	Ophthalmic micellar compositions with enhanced stability
US20090169629A1 (en) *	2008-01-02	2009-07-02	Novagali Pharma Sa	Micellar compositions with ophthalmic applications
CA2725523C (en) *	2008-05-28	2017-01-10	Alcon Research, Ltd.	Self-preserved emulsions
EP2228057A1 (en) *	2009-03-04	2010-09-15	Novagali Pharma S.A.	Cationic oil-in-water emulsions containing prostaglandins and uses thereof
EP2228058A1 (en) *	2009-03-04	2010-09-15	Novagali Pharma S.A.	Anionic oil-in-water emulsion containing prostaglandins and uses thereof
EP2389939A1 (en) *	2010-05-28	2011-11-30	Novagali Pharma S.A.	Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions

2004
- 2004-11-09 EP EP04292645A patent/EP1655021B1/en not_active Expired - Lifetime
- 2004-11-09 ES ES04292645T patent/ES2314354T3/es not_active Expired - Lifetime
- 2004-11-09 AT AT04292645T patent/ATE412400T1/de not_active IP Right Cessation
- 2004-11-09 DE DE602004017477T patent/DE602004017477D1/de not_active Expired - Lifetime
- 2004-11-18 US US10/991,346 patent/US8298568B2/en active Active
2005
- 2005-10-10 MX MX2007005545A patent/MX2007005545A/es active IP Right Grant
- 2005-10-10 AT AT05802097T patent/ATE412401T1/de not_active IP Right Cessation
- 2005-10-10 AT AT05795930T patent/ATE418964T1/de not_active IP Right Cessation
- 2005-10-10 CN CNA2005800300698A patent/CN101014317A/zh active Pending
- 2005-10-10 PT PT05802097T patent/PT1809238E/pt unknown
- 2005-10-10 ES ES05800012T patent/ES2319129T3/es not_active Expired - Lifetime
- 2005-10-10 ES ES05795930T patent/ES2320574T3/es not_active Expired - Lifetime
- 2005-10-10 DE DE602005010733T patent/DE602005010733D1/de not_active Expired - Lifetime
- 2005-10-10 PT PT05795930T patent/PT1809237E/pt unknown
- 2005-10-10 NZ NZ554929A patent/NZ554929A/en not_active IP Right Cessation
- 2005-10-10 MX MX2007003045A patent/MX2007003045A/es active IP Right Grant
- 2005-10-10 DK DK05795930T patent/DK1809237T3/da active
- 2005-10-10 DE DE602005026464T patent/DE602005026464D1/de not_active Expired - Lifetime
- 2005-10-10 AT AT08102553T patent/ATE498392T1/de not_active IP Right Cessation
- 2005-10-10 US US11/667,129 patent/US8273362B2/en active Active
- 2005-10-10 ES ES05802097T patent/ES2317319T3/es not_active Expired - Lifetime
- 2005-10-10 DE DE602005012136T patent/DE602005012136D1/de not_active Expired - Lifetime
- 2005-10-10 CN CN201310241506.7A patent/CN103356481B/zh not_active Expired - Fee Related
- 2005-10-10 US US11/667,355 patent/US8372434B2/en active Active
- 2005-10-10 ZA ZA200703751A patent/ZA200703751B/xx unknown
- 2005-10-10 DE DE602005011480T patent/DE602005011480D1/de not_active Expired - Lifetime
- 2005-10-10 US US11/665,066 patent/US8298569B2/en active Active
- 2005-10-10 CN CN2005800383296A patent/CN101056615B/zh not_active Expired - Lifetime
- 2005-10-10 AT AT05800012T patent/ATE415942T1/de not_active IP Right Cessation
2006
- 2006-10-10 US US12/089,609 patent/US20080268020A1/en not_active Abandoned
2007
- 2007-02-20 IL IL181446A patent/IL181446A/en active IP Right Grant
- 2007-05-01 IL IL182897A patent/IL182897A/en unknown
2008
- 2008-03-27 IL IL190497A patent/IL190497A/en active IP Right Grant
2012
- 2012-04-05 JP JP2012086806A patent/JP5587936B2/ja not_active Expired - Fee Related
- 2012-05-15 JP JP2012111941A patent/JP5773941B2/ja not_active Expired - Fee Related
2014
- 2014-02-19 JP JP2014029816A patent/JP5894202B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
ES2319129T3 (es)	2009-05-04
NZ554929A (en)	2010-09-30
ATE498392T1 (de)	2011-03-15
JP5894202B2 (ja)	2016-03-23
CN103356481A (zh)	2013-10-23
US20090028955A1 (en)	2009-01-29
CN101014317A (zh)	2007-08-08
ATE415942T1 (de)	2008-12-15
JP2012162549A (ja)	2012-08-30
US20070248645A1 (en)	2007-10-25
JP2014088450A (ja)	2014-05-15
JP2012149102A (ja)	2012-08-09
DE602005012136D1 (de)	2009-02-12
MX2007005545A (es)	2007-07-05
IL181446A0 (en)	2007-07-04
DE602005026464D1 (de)	2011-03-31
CN103356481B (zh)	2017-11-28
DE602005010733D1 (de)	2008-12-11
IL181446A (en)	2010-06-16
IL190497A0 (en)	2008-11-03
US8298568B2 (en)	2012-10-30
JP5587936B2 (ja)	2014-09-10
US8298569B2 (en)	2012-10-30
JP5773941B2 (ja)	2015-09-02
HK1112411A1 (en)	2008-09-05
CN101056615A (zh)	2007-10-17
MX2007003045A (es)	2007-08-02
IL190497A (en)	2012-01-31
ATE418964T1 (de)	2009-01-15
ES2314354T3 (es)	2009-03-16
US8273362B2 (en)	2012-09-25
IL182897A0 (en)	2007-08-19
US20080107738A1 (en)	2008-05-08
PT1809238E (pt)	2009-02-09
EP1655021B1 (en)	2008-10-29
US8372434B2 (en)	2013-02-12
PT1809237E (pt)	2009-04-09
ATE412401T1 (de)	2008-11-15
CN101056615B (zh)	2011-05-11
DE602004017477D1 (de)	2008-12-11
US20080268020A1 (en)	2008-10-30
ATE412400T1 (de)	2008-11-15
IL182897A (en)	2010-12-30
ZA200703751B (en)	2008-08-27
EP1655021A1 (en)	2006-05-10
DE602005011480D1 (de)	2009-01-15
ES2320574T3 (es)	2009-05-25
US20060100288A1 (en)	2006-05-11
ES2317319T3 (es)	2009-04-16
HK1107938A1 (en)	2008-04-25

Publication	Publication Date	Title
DK1809237T3 (da)	2009-05-04	Ophthalmisk olie-i-vand emulsion med stabilt positivt zeta-potentiale
BRPI0506983A (pt)	2007-07-03	composições para terapia localizada dos olhos, compreendendo preferencialmente acetonida de triancinolona e ácido hialurÈnico
BRPI0411306A (pt)	2006-07-11	composições farmacêuticas compreendendo compostos ativos de vitamina d
EA200600877A1 (ru)	2006-12-29	Наночастицы для доставки лекарств
WO2006050837A3 (en)	2006-11-16	Ophthalmic emulsions containing an immunosuppressive agent
WO2007027941A3 (en)	2007-04-26	Compositions and methods for preparation of poorly water soluble drugs with increased stability
WO2008070538A3 (en)	2008-11-06	Micellar nanoparticles comprising botulinum toxin
WO2005049091A3 (en)	2006-11-09	Antibody-targeted nanoparticulate active agent delivery
WO2007137237A3 (en)	2008-12-18	Treatment of protein misfolding
WO2002083097A3 (en)	2003-03-13	Drug delivery system for hydrophobic drugs
CY1110264T1 (el)	2015-01-14	Φαρμακευτικες συνθεσεις που περιλαμβανουν ευαισθητα σε ρη συμπολυμερη τυπου μπλοκ και υδροφοβο φαρμακο
EP2004172A4 (en)	2013-01-02	ACTIVE INK PROCESSING, STRUCTURES AND COMPOSITIONS FOR NASOLACRIMAL SYSTEM
MXPA05002814A (es)	2005-05-27	Formulacion para agentes lipofilicos.
DE60216305D1 (de)	2007-01-04	Zusammensetzungen zur verabreichung von arzneimittelkombinationen
EP1796629A4 (en)	2013-01-09	SEMICONDUCTORY DISPENSER AND PHARMACEUTICAL COMPOSITIONS
WO2004087052A3 (en)	2004-11-18	Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent
ATE439123T1 (de)	2009-08-15	Verwendung von emulsionen zur intra- und periocularen injection
MD20070267A (en)	2008-06-30	Gastroresistant pharmaceutical formulation containing rifaximin
BRPI0414721A (pt)	2006-11-21	formulações estabilizadas de fosfatidilserina
WO2008067164A3 (en)	2008-12-18	Solid pharmaceutical dosage formulations
ATE507818T1 (de)	2011-05-15	Orale verabreichung eines calcitonins
UA89315C2 (en)	2010-01-11	Butylbenzene phthalein intravenous emulsion
SI1561460T1 (sl)	2007-06-30	Nanodelci za aplikacijo uäśinkovin, postopek za pripravo teh delcev in sestavek, ki jih vsebuje
Salamah et al.	2025	Development and Characterization of In Situ Gelling Nasal Cilostazol Spanlastics
WO2008048205A3 (en)	2008-09-04	Method for delivering hydrophobic drugs via nanocrystal formulations